Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

• Status: Completed
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Cognitive training is moderately effective at reducing symptoms and improving life function in schizophrenia patients. The present application develops a strategy for increasing the effectiveness of cognitive training through the use of pro-cognitive medications. Specific biomarkers will be studied that identify patients most sensitive to these pro-cognitive medications, to test the feasibility of using these biomarkers in a large clinical trial of medication-enhanced cognitive training in schizophrenia.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Memantine

Criteria

Inclusion Criteria:

• A diagnosis of schizophrenia or schizoaffective disorder - depressed type

Exclusion Criteria:

• Age range,

• Current alcohol or drug abuse